NO993943L - Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer - Google Patents

Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer

Info

Publication number
NO993943L
NO993943L NO993943A NO993943A NO993943L NO 993943 L NO993943 L NO 993943L NO 993943 A NO993943 A NO 993943A NO 993943 A NO993943 A NO 993943A NO 993943 L NO993943 L NO 993943L
Authority
NO
Norway
Prior art keywords
tumor suppressor
treatment
neoplasms
chemotherapy
combined tumor
Prior art date
Application number
NO993943A
Other languages
English (en)
Other versions
NO993943D0 (no
Inventor
Loretta Nielsen
Jo Ann Horowitz
Daniel C Maneval
William G Demers
Mary Ellen Rybak
Gene Resnick
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of NO993943D0 publication Critical patent/NO993943D0/no
Publication of NO993943L publication Critical patent/NO993943L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
NO993943A 1997-02-18 1999-08-17 Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer NO993943L (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US80176597A 1997-02-18 1997-02-18
US80128597A 1997-02-18 1997-02-18
US3806597P 1997-02-18 1997-02-18
US80175597A 1997-02-18 1997-02-18
US80168197A 1997-02-18 1997-02-18
US4783497P 1997-05-28 1997-05-28
PCT/US1998/003514 WO1998035554A2 (en) 1997-02-18 1998-02-17 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Publications (2)

Publication Number Publication Date
NO993943D0 NO993943D0 (no) 1999-08-17
NO993943L true NO993943L (no) 1999-10-15

Family

ID=27556335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993943A NO993943L (no) 1997-02-18 1999-08-17 Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer

Country Status (19)

Country Link
EP (1) EP0969720B1 (no)
JP (1) JP2001511815A (no)
KR (2) KR100688409B1 (no)
CN (1) CN1248731C (no)
AT (1) ATE361668T1 (no)
AU (1) AU737621B2 (no)
BR (1) BR9807418A (no)
CA (1) CA2282683A1 (no)
CZ (1) CZ298488B6 (no)
DE (1) DE69837754T2 (no)
ES (1) ES2287974T3 (no)
HK (1) HK1026579A1 (no)
HU (1) HUP0004326A3 (no)
IL (2) IL131447A0 (no)
NO (1) NO993943L (no)
NZ (1) NZ337283A (no)
PL (1) PL193767B1 (no)
SK (1) SK285969B6 (no)
WO (1) WO1998035554A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
HUP9901908A3 (en) 1995-07-17 2000-02-28 Univ Texas P16 expression constructs and their application in cancer therapy
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
CA2315693C (en) * 1997-12-22 2010-11-30 Schering Corporation Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
AU762986B2 (en) * 1998-04-22 2003-07-10 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and conventional drugs
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2000056351A2 (en) * 1999-03-19 2000-09-28 Schering Corporation Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
ATE481640T1 (de) * 2000-11-27 2010-10-15 Minerva Biotechnologies Corp Diagnostika, drogenscreening und behandlung für krebs
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
CA2548220A1 (en) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
WO2005061001A1 (ja) * 2003-12-24 2005-07-07 Locomogene, Inc. 癌の抑制方法
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
JP2008518632A (ja) 2004-11-03 2008-06-05 イントロゲン セラピューティックス， インコーポレイテッド アデノウイルスベクターの製造および精製のための新規方法
CN107660213B (zh) 2015-02-10 2023-01-13 米纳瓦生物技术公司 人源化抗MUCl＊抗体
CN108030931A (zh) * 2017-03-07 2018-05-15 大连民族大学 一种药物脂质体/p53基因复合物的应用
CN109200295A (zh) * 2018-10-08 2019-01-15 蚌埠医学院 一种用于治疗卵巢癌的药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
ES2164717T3 (es) * 1993-10-15 2002-03-01 Schering Corp Compuestos triciclicos de sulfonamida utiles para inhibir la funcion de la proteina-g y para el tratamiento de enfermedades proliferativas.
CA2240846C (en) * 1995-12-22 2002-07-16 Schering Corporation Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases

Also Published As

Publication number Publication date
CN1248731C (zh) 2006-04-05
HUP0004326A2 (hu) 2001-02-28
ES2287974T3 (es) 2007-12-16
CA2282683A1 (en) 1998-08-20
IL195605A0 (en) 2011-08-01
AU737621B2 (en) 2001-08-23
CN1252689A (zh) 2000-05-10
ATE361668T1 (de) 2007-06-15
IL131447A0 (en) 2001-01-28
AU6438098A (en) 1998-09-08
EP0969720A2 (en) 2000-01-12
HUP0004326A3 (en) 2003-07-28
JP2001511815A (ja) 2001-08-14
DE69837754D1 (de) 2007-06-21
WO1998035554A3 (en) 1998-11-26
EP0969720A4 (en) 2004-05-12
DE69837754T2 (de) 2008-02-07
PL193767B1 (pl) 2007-03-30
CZ298488B6 (cs) 2007-10-17
KR100620939B1 (ko) 2006-09-06
HK1026579A1 (en) 2000-12-22
WO1998035554A2 (en) 1998-08-20
KR100688409B1 (ko) 2007-03-02
NZ337283A (en) 2001-02-23
SK285969B6 (sk) 2007-12-06
KR20000071185A (ko) 2000-11-25
KR20050113287A (ko) 2005-12-01
SK112299A3 (en) 2000-12-11
CZ293399A3 (cs) 2000-03-15
EP0969720B1 (en) 2007-05-09
PL335334A1 (en) 2000-04-25
NO993943D0 (no) 1999-08-17
BR9807418A (pt) 2002-01-22

Similar Documents

Publication Publication Date Title
IL195605A0 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
EP1004022A4 (en) METHODS AND COMPOSITIONS FOR OVERCOMING RESISTANCE TO BIOLOGICAL THERAPY AND CHEMOTHERAPY
HK1030624A1 (en) Enzyme catalyzed therapeutic agents
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
DE69837529D1 (de) Proteinmarker für lungenkrebs und deren verwendung
CY1109367T1 (el) Συνθεσεις και μεθοδοι για ενισχυση της παροχης θεραπευτικων παραγοντων σε κυτταρα
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
DE60041592D1 (de) Testverfahren für verbindungen die frühzeitige tra
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
AU6249098A (en) Method of treating cancer using alkylglycerols in conjunction with chemotherapy
ATE285247T1 (de) Krebstherapie mit lymphotoxin
DE69735676D1 (de) Proteinmarker für ösophaguskrebs
WO2000056351A3 (en) Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
GB9723824D0 (en) Cytostatic agents
CO5080825A1 (es) Sistema de terapia con genes suicidas para el tratamiento de tumores cerebrales
DE60023695D1 (de) Tumorsuppressormoleküle und nutzungsverfahren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application